Pathology (PSR)

项目摘要/摘要：病理学 病理共享资源(PSR)，指定的诺里斯棉花癌中心(NCCC)共享资源 设施，为NCCC调查人员提供访问最新的生物库和 在CLIA许可、CAP认证的实验室环境中进行生物标记物测试。CLIA/CAP标准为 对支持临床试验、生物标志物发现研究以及将研究成果转化为 临床测试。PSR位于临床基因组学和高级实验室的保护伞下 病理和检验医学系的技术(CGAT)。主要PSR服务范围 组织学、基因组学、细胞疗法和机构生物库。自上次审查以来，共享的 资源已经搬进了威廉姆森翻译研究大楼10,000平方英尺的新空间。实验室 购买了Ion Torrent Chef-55系统，以支持其作为成人和 儿童NCI匹配试验。下一代测序服务现在包括一个50个基因的癌症热点 Panel，一个50基因的实体肿瘤融合基因小组，和一个54基因的髓系小组，导致体细胞突变 超过4,000名患者肿瘤的数据库现在可用于研究人员发起的数据挖掘。为成人准备的 匹配试验，实验室已经对280个样本进行了测序，对于儿科匹配试验，我们有 到目前为止，对292个样本进行了测序。PSR已经建立了一个体细胞突变数据库，用于常规检测 人类癌症，包括胶质瘤、三阴性乳腺癌、非小细胞肺癌、转移性 结直肠癌、转移性黑色素瘤、胃肠道间质瘤、肉瘤和急性髓系白血病。 这些数据导致了许多多学科的出版物，评估了和 不同类型的肿瘤。机构生物信息库样本在eSample中进行注释，eSample是Velos的一个模块， 由NCCC支持，并与临床试验计划eResearch连接，eResearch也是Velos中的一个模块。 I2B2连接将促进个性化医学中靶向治疗的设计。自2014年以来，PSR已经 在所有四个计划中，为60名NCCC现有成员提供了20,000多个单位的服务。受资助的NCCC 自2015年以来，会员已占总用户数的77%(49)，而我们仅申请了总用户数的38% 来自CCSG支持的PSR预算。多重免疫组化检测、免疫荧光和扩增基因 正在开发突变面板，以进一步支持更先进的研究人员驱动的应用程序。在……里面 此外，该实验室继续开发无细胞DNA分析，并扩大机构生物库 随着BC平台标本/数据仓库软件的实施，将允许调查人员门户 获取具有临床和基因组数据的独立法案审查(IBR)样本。

Project Summary/Abstract: Pathology The Pathology Shared Resource (PSR), a designated Norris Cotton Cancer Center (NCCC) Shared Resource facility, was created to provide NCCC investigators access to the latest technologies for biobanking and biomarker testing in a CLIA-licensed, CAP-accredited laboratory environment. The CLIA/CAP standards are essential to the support of clinical trials, biomarker discovery studies, and the transition of research findings to clinical testing. The PSR is housed under the umbrella of the laboratory for Clinical Genomics and Advanced Technology (CGAT) in the Department of Pathology and Laboratory Medicine. Major PSR services span histology, genomics, cell therapy, and the institutional biorepository. Since the last review, the Shared Resource has moved into 10,000 sf of new space in the Williamson Translational Research Building. The lab acquired an Ion Torrent Chef-55 system to support its role as a central reference lab for both the adult and pediatric NCI MATCH trials. Next generation sequencing services now include a 50-gene cancer hotspot panel, a 50-gene solid tumor fusion gene panel, and a 54-gene myeloid panel, resulting in a somatic mutation database of more than 4,000 patient tumors now available for investigator-initiated data mining. For the Adult MATCH trial, the laboratory has sequenced 280 samples, and for the Pediatric MATCH trial we have sequenced 292 samples to date. The PSR has established a somatic mutation database for routinely tested human cancers that includes glioma, triple negative breast cancer, non-small cell lung cancer, metastatic colorectal cancer, metastatic melanoma, gastrointestinal stromal tumor, sarcoma, and acute myeloid leukemia. These data have resulted in numerous multidisciplinary publications evaluating mutation profiles within and across tumor types. Institutional biorepository samples are annotated in eSample, a module of Velos which is supported by the NCCC and has connectivity with the clinical trial program eResearch, also a module in Velos. I2B2 connectivity will facilitate the design of targeted therapies in personalized medicine. Since 2014, PSR has provided over 20,000 units of service to 60 current NCCC Members across all four Programs. Funded NCCC Members since 2015 have represented 77% (49) of Total Users, and we are requesting only 38% of the Total PSR budget from CCSG support. Additional multiplex IHC assays, immunofluorescence and expanded gene mutation panels are being developed to further support more advanced investigator-driven applications. In addition, the laboratory continues to develop cell-free DNA assays and expand the institutional biorepository with implementation of the BC Platform specimen/data warehousing software that will allow investigators portal access to Independent Bill Review (IBR) specimens curated with clinical and genomic data.